GlycoMimetics, Inc. (GLYC) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1154913,
    "name": "GlycoMimetics, Inc.",
    "stock_name": "GlycoMimetics, Inc.",
    "full_name": "GlycoMimetics, Inc.",
    "name_url": "stocks-analysis/glycomimetics-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "12.99",
    "chg": -0.1,
    "chgp": "-0.76%",
    "dir": -1,
    "prev_price": "13.09",
    "mcapval": "201.03",
    "mcap": "",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "US38000Q1022",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "941.24 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/glycomimetics-inc-1154913-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is GlycoMimetics, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-glycomimetics-inc-technically-bullish-or-bearish-3546606",
        "imagepath": "",
        "date": "2025-09-20 19:36:46",
        "description": "As of 2 September 2025, the technical trend for GlycoMimetics, Inc. has changed from bullish to mildly bullish. The weekly MACD is mildly bearish, while the monthly MACD is bullish. The RSI indicates bearish conditions on both the weekly and monthly time frames. Bollinger Bands show a bullish stance weekly and mildly bullish monthly. Daily moving averages are mildly bullish, while the KST is bullish on both weekly and monthly periods. Dow Theory suggests a mildly bearish trend weekly with no trend monthly, and OBV is mildly bearish on both time frames.\n\nIn terms of performance, the stock has significantly outperformed the S&P 500 year-to-date with a return of 5096.79% compared to the S&P 500's 12.22%. However, over the past month, the stock has underperformed, returning -6.16% against the S&P 500's 2.33%. Overall, the current technical stance is mildly bullish, driven by the monthly MACD and KST indicators,..."
      },
      {
        "title": "Is GlycoMimetics, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-glycomimetics-inc-overvalued-or-undervalued-3543145",
        "imagepath": "",
        "date": "2025-09-20 18:11:54",
        "description": "As of 28 April 2022, the valuation grade for GlycoMimetics, Inc. moved from risky to does not qualify, indicating a significant decline in its investment attractiveness. The company is currently overvalued, as evidenced by its Price to Book Value of 3.71 and a negative EV to EBIT and EV to EBITDA of -0.29, which suggest that the market is pricing the stock at a premium despite its lack of profitability. Additionally, the Return on Equity (ROE) is alarmingly low at -650.50%, further underscoring the company's financial struggles.\n\nIn comparison to its peers, GlycoMimetics shows a P/E ratio of -5.9739, while DiaMedica Therapeutics, Inc. has a P/E of -12.5116, and Abeona Therapeutics, Inc. has a P/E of 5.4453, highlighting the relative valuation challenges faced by GlycoMimetics. The stock has performed exceptionally well year-to-date with a return of 5096.79%, significantly outpacing the S&P 500's 12.22% retu..."
      }
    ],
    "total": 7,
    "sid": "1154913",
    "stock_news_url": "https://www.marketsmojo.com/news/glycomimetics-inc-1154913"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is GlycoMimetics, Inc. technically bullish or bearish?

2025-09-20 19:36:46

As of 2 September 2025, the technical trend for GlycoMimetics, Inc. has changed from bullish to mildly bullish. The weekly MACD is mildly bearish, while the monthly MACD is bullish. The RSI indicates bearish conditions on both the weekly and monthly time frames. Bollinger Bands show a bullish stance weekly and mildly bullish monthly. Daily moving averages are mildly bullish, while the KST is bullish on both weekly and monthly periods. Dow Theory suggests a mildly bearish trend weekly with no trend monthly, and OBV is mildly bearish on both time frames. In terms of performance, the stock has significantly outperformed the S&P 500 year-to-date with a return of 5096.79% compared to the S&P 500's 12.22%. However, over the past month, the stock has underperformed, returning -6.16% against the S&P 500's 2.33%. Overall, the current technical stance is mildly bullish, driven by the monthly MACD and KST indicators,...

Is GlycoMimetics, Inc. overvalued or undervalued?

2025-09-20 18:11:54

As of 28 April 2022, the valuation grade for GlycoMimetics, Inc. moved from risky to does not qualify, indicating a significant decline in its investment attractiveness. The company is currently overvalued, as evidenced by its Price to Book Value of 3.71 and a negative EV to EBIT and EV to EBITDA of -0.29, which suggest that the market is pricing the stock at a premium despite its lack of profitability. Additionally, the Return on Equity (ROE) is alarmingly low at -650.50%, further underscoring the company's financial struggles. In comparison to its peers, GlycoMimetics shows a P/E ratio of -5.9739, while DiaMedica Therapeutics, Inc. has a P/E of -12.5116, and Abeona Therapeutics, Inc. has a P/E of 5.4453, highlighting the relative valuation challenges faced by GlycoMimetics. The stock has performed exceptionally well year-to-date with a return of 5096.79%, significantly outpacing the S&P 500's 12.22% retu...

View All News